Choosing Osteoporosis Treatment: Using the Full Spectrum of Therapies
Sponsored by the American Society for Bone and Mineral Research
- Be familiar with the pros and cons of standard therapy for osteoporosis.
- Understand that differences in efficacy among bisphosphonates, teriparatide, and denosumab in reducing fracture risk are small.
- Be able to make therapeutic decisions in specific patients, based on risks and benefits.
Robert A. Adler, M.D.
Dr. Robert A. Adler is Chief of Endocrinology at the McGuire Veterans Affairs Medical Center in Richmond, Virginia and Professor of Internal Medicine at Virginia Commonwealth University School of Medicine. His research interests include screening men for osteoporosis, osteoporosis in patients with mobility disorders, and improving osteoporosis care in high risk patient populations. Dr. Adler was a member of the ASBMR Atypical Femoral Fractures Task Force and the Endocrine Society Male Osteoporosis Guidelines Committee. He is a member of ASBMR Council.
The American Society for Bone and Mineral Research presents this information for educational purposes only. The content is provided solely by faculty who has been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. ASBMR assume no liability for the information herein.
Copyright © 2013 American Society for Bone and Mineral Research . Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:
The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without American Society for Bone and Mineral Research’s prior written permission.